T cell receptors that bind to presented HPV16, MART1, CMV, EBV, or influenza peptides.
TCRs with defined epitope specificity, identified via RAPTER, address the limitations of antibody therapies by effectively targeting intracellular antigens, enhancing T cell responses for HPV-16, MART1, EBV, or influenza diseases.
JP2026518435APending Publication Date: 2026-06-08REGENERON PHARMACEUTICALS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- REGENERON PHARMACEUTICALS INC
- Filing Date
- 2024-05-24
- Publication Date
- 2026-06-08
Smart Images
Figure 2026518435000001_ABST
Abstract
This specification describes isolated T cell receptors that specifically bind to HLA-presenting HPV16, MART1, CMV, EBV, or influenza peptides, as well as therapeutic and diagnostic methods using their isolated TCRs. This specification describes low-frequency circulating HPV16-specific T cell clones derived from cervical cancer patients. Furthermore, this specification describes T cell receptors (TCRs) identified by RAPTER that target MART1, EBV, CMV, and influenza epitopes, and are functionally confirmed in in vitro assays.
Need to check novelty before this filing date? Find Prior Art